Pharmacokinetics, withdrawal period and risk assessment of enrofloxacin in the northern snakehead (Channa argus) following bath administration

IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY
Meiling Zhang, Guangming Zheng, Yi Yin, Hao Zhou, Lisha Ma, Lichun Li, Jiawei Lin, Shugui Liu, Cheng Zhao, Xiaoxin Dai, Linting Wei, Qi Shan
{"title":"Pharmacokinetics, withdrawal period and risk assessment of enrofloxacin in the northern snakehead (Channa argus) following bath administration","authors":"Meiling Zhang,&nbsp;Guangming Zheng,&nbsp;Yi Yin,&nbsp;Hao Zhou,&nbsp;Lisha Ma,&nbsp;Lichun Li,&nbsp;Jiawei Lin,&nbsp;Shugui Liu,&nbsp;Cheng Zhao,&nbsp;Xiaoxin Dai,&nbsp;Linting Wei,&nbsp;Qi Shan","doi":"10.1111/jvp.13413","DOIUrl":null,"url":null,"abstract":"<p>Enrofloxacin (ENR) is widely used in aquaculture practice, but little is known about its pharmacokinetic, withdrawal period and dietary risk in fish via bath administration. The purpose of this study was to provide data support for the use of ENR bath therapy in the northern snakehead (<i>Channa argus</i>). The pilot study was carried out to evaluate the therapy concentrations of ENR in northern snakehead with immersion concentrations ranged from 5 to 40 mg/L for 6 h. Based on results of the pilot study, an ENR immersion concentration of 20 mg/L was used for the formal experiment. At this dose, the peak concentrations of ENR in plasma, muscle plus skin, liver and kidney were 4.85, 4.55, 3.87 and 7.42 μg/mL (or g), respectively. According to the AUC<sub>0-∞</sub> values, the distribution of ENR in northern snakehead followed the order of kidney &gt; plasma &gt; liver &gt; muscle + skin. The elimination of ENR in northern snakehead was very slow, the half-lives (T<sub>1/2λ<i>z</i></sub>) were up to 90.31, 85.5, 104.56 and 120.9 h in plasma, muscle plus skin, liver and kidney, respectively. Ciprofloxacin (CIP) was not detected in any samples in the pilot study and was only occasionally detected in muscle plus skin and liver samples in formal experiment. Based on the calculated PK/PD index AUC/MIC and <i>C</i><sub>max</sub>/MIC, the current bath treatment regimen will have a good therapeutic effect on infections caused by bacteria with MIC below 0.6 μg/mL. The dietary risk assessment suggested that there was a dietary risk (Hazard Quotients &gt; 10%) until day 6 after bath treatment. It is mandatory for ENR to maintain a withdrawal period of at least 450°C-day in northern snakehead after bath treatment ceased.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 2","pages":"134-142"},"PeriodicalIF":1.5000,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvp.13413","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Enrofloxacin (ENR) is widely used in aquaculture practice, but little is known about its pharmacokinetic, withdrawal period and dietary risk in fish via bath administration. The purpose of this study was to provide data support for the use of ENR bath therapy in the northern snakehead (Channa argus). The pilot study was carried out to evaluate the therapy concentrations of ENR in northern snakehead with immersion concentrations ranged from 5 to 40 mg/L for 6 h. Based on results of the pilot study, an ENR immersion concentration of 20 mg/L was used for the formal experiment. At this dose, the peak concentrations of ENR in plasma, muscle plus skin, liver and kidney were 4.85, 4.55, 3.87 and 7.42 μg/mL (or g), respectively. According to the AUC0-∞ values, the distribution of ENR in northern snakehead followed the order of kidney > plasma > liver > muscle + skin. The elimination of ENR in northern snakehead was very slow, the half-lives (T1/2λz) were up to 90.31, 85.5, 104.56 and 120.9 h in plasma, muscle plus skin, liver and kidney, respectively. Ciprofloxacin (CIP) was not detected in any samples in the pilot study and was only occasionally detected in muscle plus skin and liver samples in formal experiment. Based on the calculated PK/PD index AUC/MIC and Cmax/MIC, the current bath treatment regimen will have a good therapeutic effect on infections caused by bacteria with MIC below 0.6 μg/mL. The dietary risk assessment suggested that there was a dietary risk (Hazard Quotients > 10%) until day 6 after bath treatment. It is mandatory for ENR to maintain a withdrawal period of at least 450°C-day in northern snakehead after bath treatment ceased.

恩诺沙星在乌鱼沐浴后的药代动力学、停药期和风险评估。
恩诺沙星(ENR)在水产养殖中有着广泛的应用,但对其在鱼类中的药代动力学、停药期和沐浴给药的饮食风险知之甚少。本研究的目的是为ENR浴疗法在北方乌鱼(Channa argus)中的应用提供数据支持。进行了一项初步研究,以评估ENR在浸泡浓度范围为5至40的北方蛇头中的治疗浓度 mg/L,6 h.根据中试研究的结果,ENR浸渍浓度为20 mg/L用于正式实验。在该剂量下,血浆、肌肉加皮肤、肝脏和肾脏中ENR的峰值浓度分别为4.85、4.55、3.87和7.42 μg/mL(或g)。根据AUC0-∞值,ENR在北方蛇头中的分布遵循肾脏的顺序 > 血浆 > 肝脏 > 肌肉 + 皮ENR在北方乌鱼体内的消除非常缓慢,半衰期(T1/2λz)分别为90.31、85.5、104.56和120.9 h分别在血浆、肌肉加皮肤、肝脏和肾脏中。环丙沙星(CIP)在试点研究中未在任何样本中检测到,在正式实验中仅在肌肉、皮肤和肝脏样本中偶尔检测到。根据计算出的PK/PD指数AUC/MIC和Cmax/MIC,目前的沐浴治疗方案对MIC低于0.6的细菌引起的感染将具有良好的治疗效果 μg/mL。饮食风险评估表明存在饮食风险(Hazard Quotients > 10%),直至浴处理后第6天。ENR在北方乌鱼停止沐浴治疗后,必须保持至少450°C天的停药期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
15.40%
发文量
69
审稿时长
8-16 weeks
期刊介绍: The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信